Kesimpta (ofatumumab) is a antibody treatment injected under the skin. The first dose should be performed under the guidance of a healthcare professional. The next 2 doses are given one week apart and then every 4 weeks. The medication removes B cells, a type of white blood cell from the body.
In ASCLEPIOS I & II trials, Kesimpta injected under the skin every 4 weeks reduced relapses 51-58% and disability progression 34-35% compared to Aubagio. In addition, Kesimpta reduced contrast MRI lesions 94-97% compared to Aubagio.
Risks include injection site reactions and potential serious infections. No cases of PML (brain viral infection) in MS clinical trials, but possible rare risk based on class of this medication (B-cell depleting medication). Antibody levels (immunoglobulin levels) can decrease on treatment with can increase risk of infection.